FDC Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Efficient capital deployment (ROCE 16.7%)
- ✓Attractively valued vs sector (P/E 23x vs industry 54.4x)
- ✓Virtually debt-free
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
FDC · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 69.66% | 69.66% | 69.66% | 69.66% | 69.66% | 69.66% |
| FII | 2.43% | 2.65% | 2.51% | 2.62% | 2.67% | 2.56% |
| DII | 7.76% | 6.94% | 6.72% | 6.02% | 6.08% | 6.37% |
| Public | 20.15% | 20.76% | 21.11% | 21.71% | 21.60% | 21.42% |
Corporate Events
Interim Dividend - Rs 5 Per Share
Interim Dividend - Rs 5 Per Share
Annual General Meeting
Annual General Meeting
Buy Back
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹585 Cr ▲25.8% | ₹465 Cr ▼1.7% | ₹473 Cr ▼27.0% | ₹648 Cr ▲31.7% | ₹492 Cr ▲6.0% | ₹464 Cr ▼9.7% | ₹514 Cr ▼19.4% | ₹638 Cr |
| Op. Profit | ₹106 Cr ▲103.8% | ₹52 Cr ▲52.9% | ₹34 Cr ▼75.7% | ₹140 Cr ▲159.3% | ₹54 Cr ▲14.9% | ₹47 Cr ▼32.9% | ₹70 Cr ▼52.4% | ₹147 Cr |
| OPM | 18.0% ▲63.6% | 11.0% ▲57.1% | 7.0% ▼68.2% | 22.0% ▲100.0% | 11.0% ▲10.0% | 10.0% ▼28.6% | 14.0% ▼39.1% | 23.0% |
| Net Profit | ₹103 Cr ▲267.9% | ₹28 Cr ▲0.0% | ₹28 Cr ▼76.9% | ₹121 Cr ▲210.3% | ₹39 Cr ▲5.4% | ₹37 Cr ▼48.6% | ₹72 Cr ▼39.5% | ₹119 Cr |
| EPS (₹) | 6.35 ▲264.9% | 1.74 ▲0.0% | 1.74 ▼76.6% | 7.45 ▲213.0% | 2.38 ▲4.4% | 2.28 ▼48.4% | 4.42 ▼39.5% | 7.31 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.2K Cr ▲3.0% | ₹2.1K Cr ▲8.5% | ₹1.9K Cr ▲8.9% | ₹1.8K Cr ▲17.0% | ₹1.5K Cr ▲14.6% | ₹1.3K Cr ▼0.7% | ₹1.3K Cr ▲23.1% | ₹1.1K Cr ▲1.4% | ₹1.1K Cr ▲6.0% | ₹1.0K Cr |
| Expenses | ₹1.8K Cr ▲2.4% | ₹1.8K Cr ▲11.2% | ₹1.6K Cr ▲4.6% | ₹1.5K Cr ▲20.6% | ₹1.3K Cr ▲27.5% | ₹997 Cr ▼3.9% | ₹1.0K Cr ▲20.7% | ₹860 Cr ▲2.3% | ₹841 Cr ▲9.4% | ₹769 Cr |
| Op. Profit | ₹346 Cr ▲6.5% | ₹325 Cr ▼4.1% | ₹339 Cr ▲35.1% | ₹251 Cr ▼1.2% | ₹254 Cr ▼24.0% | ₹334 Cr ▲9.9% | ₹304 Cr ▲32.8% | ₹229 Cr ▼1.7% | ₹233 Cr ▼4.1% | ₹243 Cr |
| OPM | 16.0% ▲6.7% | 15.0% ▼11.8% | 17.0% ▲21.4% | 14.0% ▼17.6% | 17.0% ▼32.0% | 25.0% ▲8.7% | 23.0% ▲9.5% | 21.0% ▼4.5% | 22.0% ▼8.3% | 24.0% |
| Other Income | ₹93 Cr ▲2.2% | ₹91 Cr ▼10.8% | ₹102 Cr ▲104.0% | ₹50 Cr ▼34.2% | ₹76 Cr ▼20.0% | ₹95 Cr ▲66.7% | ₹57 Cr ▲35.7% | ₹42 Cr ▼6.7% | ₹45 Cr ▲2.3% | ₹44 Cr |
| Interest | ₹5 Cr ▲0.0% | ₹5 Cr ▲25.0% | ₹4 Cr ▲0.0% | ₹4 Cr ▲33.3% | ₹3 Cr ▲0.0% | ₹3 Cr ▲0.0% | ₹3 Cr ▲200.0% | ₹1 Cr ▲0.0% | ₹1 Cr ▲0.0% | ₹1 Cr |
| Depreciation | ₹59 Cr ▲9.3% | ₹54 Cr ▲35.0% | ₹40 Cr ▲2.6% | ₹39 Cr ▲5.4% | ₹37 Cr ▼2.6% | ₹38 Cr ▲2.7% | ₹37 Cr ▲12.1% | ₹33 Cr ▼5.7% | ₹35 Cr ▲0.0% | ₹35 Cr |
| PBT | ₹375 Cr ▲5.0% | ₹357 Cr ▼9.8% | ₹396 Cr ▲53.5% | ₹258 Cr ▼10.7% | ₹289 Cr ▼25.5% | ₹388 Cr ▲21.3% | ₹320 Cr ▲35.0% | ₹237 Cr ▼1.7% | ₹241 Cr ▼4.4% | ₹252 Cr |
| Tax % | 25.0% ▲0.0% | 25.0% ▲8.7% | 23.0% ▼8.0% | 25.0% ▲0.0% | 25.0% ▲13.6% | 22.0% ▼12.0% | 25.0% ▼10.7% | 28.0% ▲0.0% | 28.0% ▲12.0% | 25.0% |
| Net Profit | ₹281 Cr ▲5.2% | ₹267 Cr ▼12.5% | ₹305 Cr ▲57.2% | ₹194 Cr ▼10.2% | ₹216 Cr ▼28.2% | ₹301 Cr ▲25.4% | ₹240 Cr ▲41.2% | ₹170 Cr ▼2.3% | ₹174 Cr ▼7.9% | ₹189 Cr |
| EPS (₹) | 17.29 ▲5.5% | 16.39 ▼12.6% | 18.75 ▲60.3% | 11.7 ▼8.7% | 12.82 ▼28.2% | 17.85 ▲27.2% | 14.03 ▲44.0% | 9.74 ▼2.1% | 9.95 ▼6.1% | 10.6 |
| Div Payout | 29.0% ▼6.5% | 31.0% | 0.0% | 0.0% | 0.0% | 0.0% ▼100.0% | 6.0% | 0.0% | 0.0% ▼100.0% | 21.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹16 Cr ▲0.0% | ₹16 Cr ▲0.0% | ₹16 Cr ▼5.9% | ₹17 Cr ▲0.0% | ₹17 Cr ▲0.0% | ₹17 Cr ▲0.0% | ₹17 Cr ▼5.6% | ₹18 Cr ▲0.0% | ₹18 Cr ▲0.0% | ₹18 Cr |
| Reserves | ₹2.5K Cr ▲9.0% | ₹2.3K Cr ▲8.8% | ₹2.1K Cr ▲5.9% | ₹2.0K Cr ▲1.3% | ₹1.9K Cr ▲13.0% | ₹1.7K Cr ▲12.2% | ₹1.5K Cr ▲7.1% | ₹1.4K Cr ▲13.4% | ₹1.3K Cr ▲0.6% | ₹1.3K Cr |
| Borrowings | ₹15 Cr ▼28.6% | ₹21 Cr ▲0.0% | ₹21 Cr ▼25.0% | ₹28 Cr ▼12.5% | ₹32 Cr ▲113.3% | ₹15 Cr ▲0.0% | ₹15 Cr ▲1400.0% | ₹1 Cr ▲0.0% | ₹1 Cr ▲0.0% | ₹1 Cr |
| Other Liabilities | ₹418 Cr ▲1.5% | ₹412 Cr ▲17.7% | ₹350 Cr ▲5.1% | ₹333 Cr ▲18.5% | ₹281 Cr ▲35.1% | ₹208 Cr ▼16.8% | ₹250 Cr ▲28.9% | ₹194 Cr ▼14.9% | ₹228 Cr ▲15.7% | ₹197 Cr |
| Total Liabilities | ₹2.9K Cr ▲7.6% | ₹2.7K Cr ▲10.0% | ₹2.5K Cr ▲5.3% | ₹2.3K Cr ▲3.2% | ₹2.3K Cr ▲16.1% | ₹2.0K Cr ▲7.9% | ₹1.8K Cr ▲10.5% | ₹1.6K Cr ▲9.0% | ₹1.5K Cr ▲2.5% | ₹1.5K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹1.0K Cr ▲17.4% | ₹852 Cr ▲25.3% | ₹680 Cr ▼2.7% | ₹699 Cr ▼0.9% | ₹705 Cr ▲2.3% | ₹689 Cr ▲2.2% | ₹674 Cr ▼1.2% | ₹682 Cr ▲1.2% | ₹674 Cr ▼0.6% | ₹678 Cr |
| CWIP | ₹96 Cr ▼29.9% | ₹137 Cr ▼47.5% | ₹261 Cr ▲31.8% | ₹198 Cr ▲88.6% | ₹105 Cr ▲452.6% | ₹19 Cr ▼20.8% | ₹24 Cr ▲100.0% | ₹12 Cr ▼7.7% | ₹13 Cr ▲116.7% | ₹6 Cr |
| Investments | ₹1.0K Cr ▲1.9% | ₹1.0K Cr ▲21.9% | ₹843 Cr ▲4.6% | ₹806 Cr ▼9.0% | ₹886 Cr ▲12.2% | ₹790 Cr ▲18.8% | ₹665 Cr ▲13.7% | ₹585 Cr ▲24.2% | ₹471 Cr ▼4.1% | ₹491 Cr |
| Other Assets | ₹775 Cr ▲11.0% | ₹698 Cr ▲2.0% | ₹684 Cr ▲6.9% | ₹640 Cr ▲11.3% | ₹575 Cr ▲25.5% | ₹458 Cr ▲1.6% | ₹451 Cr ▲25.3% | ₹360 Cr ▲3.4% | ₹348 Cr ▲18.8% | ₹293 Cr |
| Total Assets | ₹2.9K Cr ▲7.6% | ₹2.7K Cr ▲10.0% | ₹2.5K Cr ▲5.3% | ₹2.3K Cr ▲3.2% | ₹2.3K Cr ▲16.1% | ₹2.0K Cr ▲7.9% | ₹1.8K Cr ▲10.5% | ₹1.6K Cr ▲9.0% | ₹1.5K Cr ▲2.5% | ₹1.5K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹200 Cr ▼37.1% | ₹318 Cr ▲43.9% | ₹221 Cr ▲42.6% | ₹155 Cr ▼4.3% | ₹162 Cr ▼21.7% | ₹207 Cr ▼17.2% | ₹250 Cr ▲123.2% | ₹112 Cr ▼25.3% | ₹150 Cr ▼2.6% | ₹154 Cr |
| Investing CF | ₹-110 Cr ▲44.7% | ₹-199 Cr ▼1070.6% | ₹-17 Cr ▼254.5% | ₹11 Cr ▲107.6% | ₹-145 Cr ▼88.3% | ₹-77 Cr ▲21.4% | ₹-98 Cr ▲19.0% | ₹-121 Cr ▼676.2% | ₹21 Cr ▲114.6% | ₹-144 Cr |
| Financing CF | ₹-93 Cr ▼1.1% | ₹-92 Cr ▲54.5% | ₹-202 Cr ▼12.2% | ₹-180 Cr ▼1700.0% | ₹-10 Cr ▲92.2% | ₹-129 Cr ▲9.2% | ₹-142 Cr | ₹0 Cr ▲100.0% | ₹-169 Cr | ₹0 Cr |
| Net Cash Flow | ₹-3 Cr ▼111.5% | ₹26 Cr ▲1200.0% | ₹2 Cr ▲114.3% | ₹-14 Cr ▼300.0% | ₹7 Cr ▲600.0% | ₹1 Cr ▼90.0% | ₹10 Cr ▲225.0% | ₹-8 Cr ▼900.0% | ₹1 Cr ▼90.9% | ₹11 Cr |
| Free Cash Flow | ₹40 Cr ▼82.4% | ₹227 Cr ▲50.3% | ₹151 Cr ▲221.3% | ₹47 Cr ▲34.3% | ₹35 Cr ▼76.4% | ₹148 Cr ▼40.1% | ₹247 Cr ▲252.9% | ₹70 Cr ▼38.6% | ₹114 Cr ▼12.3% | ₹130 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 26d ▲36.8% | 19d ▼13.6% | 22d ▼12.0% | 25d ▲25.0% | 20d ▼33.3% | 30d ▼11.8% | 34d ▲17.2% | 29d ▲3.6% | 28d ▲3.7% | 27d |
| Inventory Days | 182d ▼2.2% | 186d ▼13.9% | 216d ▲18.0% | 183d ▼12.9% | 210d ▲11.1% | 189d ▲5.0% | 180d ▼2.2% | 184d ▲10.8% | 166d ▲12.2% | 148d |
| Days Payable | 106d ▲3.9% | 102d ▼1.0% | 103d ▲4.0% | 99d ▲5.3% | 94d ▲38.2% | 68d ▼32.7% | 101d ▲23.2% | 82d ▼18.8% | 101d ▲24.7% | 81d |
| Cash Conv. Cycle | 102d ▼1.0% | 103d ▼23.7% | 135d ▲23.9% | 109d ▼19.3% | 135d ▼11.2% | 152d ▲34.5% | 113d ▼13.7% | 131d ▲40.9% | 93d ▼1.1% | 94d |
| Working Capital Days | 121d ▲266.7% | 33d ▼37.7% | 53d ▲10.4% | 48d ▲6.7% | 45d ▼6.3% | 48d ▲20.0% | 40d ▼11.1% | 45d ▲55.2% | 29d ▲26.1% | 23d |
| ROCE | 17.0% ▲6.3% | 16.0% ▼11.1% | 18.0% ▲38.5% | 13.0% ▼13.3% | 15.0% ▼31.8% | 22.0% ▲4.8% | 21.0% ▲23.5% | 17.0% ▼10.5% | 19.0% ▼9.5% | 21.0% |
Source: Screener.in · Lower days = better efficiency
About FDC Limited
FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets.[1]
Healthcare · Pharmaceuticals & Biotechnology